NexImmune, Inc.

OTCPK:NEXI Stock Report

Market Cap: US$139.0

NexImmune Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for NexImmune.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Sep 07

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Neximmune GAAP EPS of -$0.69 misses by $0.01

Neximmune press release (NASDAQ:NEXI): Q2 GAAP EPS of -$0.69 misses by $0.01. Shares +3.2% AH. Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related cancers Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22 Clinical updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 4Q22 Company is prioritizing resources to support Company’s lead product candidates, NEXI-001 and NEXI-003
Seeking Alpha • Jul 14

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune (NASDAQ:NEXI) stock jumped 23% postmarket on Thursday after the firm received investigational new drug clearance by FDA for its first cellular therapy candidate for solid tumors. NEXI-003, an autologous antigen-specific T cell product, is being developed for patients with relapsed or refractory HPV-related cancers. The IND clearance allows NEXI to begin phase 1 clinical trial to evaluate NEXI-003 for treatment of HPV-related cancers. The proposed study is a 2-part, multicenter, open-label, dose-finding, first-in-human study to evaluate safety and clinical activity of NEXI-003. "The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24-36 patients overall," NEXI said in a statement. After initial data and recommended phase 2 dose has been confirmed, NEXI plans to expand the NEXI-003 development program to include other HPV-related cancers and evaluate potential SOC combination options. NEXI stock has fallen 69% YTD.
Seeking Alpha • May 31

NexImmune: Selling For Under Cash Value

Shares of immune biopharma NexImmune have cratered 90% from their IPO pricing as early returns from two Phase 1/2 trials have failed to impress. In theory, the output from its AIM platform should improve upon CAR T therapies, as they are more specific and thus should be more effective and less toxic. Trading at a discount to cash, but with only enough to get NexImmune to 2Q23 (covering two data updates in 2H22), the recent purchases by three insiders merited further investigation. A full investment analysis follows in the paragraphs below.
Analysis Article • May 26

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 19

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NexImmune has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:NEXI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-21-18-18N/A
3/31/2024N/A-26-22-22N/A
12/31/2023N/A-32-31-31N/A
9/30/2023N/A-44-37-37N/A
6/30/2023N/A-49-42-41N/A
3/31/2023N/A-57-48-47N/A
12/31/2022N/A-63-52-51N/A
9/30/2022N/A-61-53-52N/A
6/30/2022N/A-61-50-49N/A
3/31/2022N/A-57-53-51N/A
12/31/2021N/A-51-48-46N/A
9/30/2021N/A-45-44-42N/A
6/30/2021N/A-39-41-39N/A
3/31/2021N/A-35-32-31N/A
12/31/2020N/A-33-27-26N/A
9/30/2020N/A-30-25-24N/A
12/31/2019N/A-23-21-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NEXI's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if NEXI's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if NEXI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NEXI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NEXI's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NEXI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 21:28
End of Day Share Price 2026/05/29 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NexImmune, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kaveri PohlmanBTIG
Alethia YoungCantor Fitzgerald & Co.